期刊文献+

基于临床病理特征富集初治NSCLC患者EGFR基因突变的相关研究

Study on enriched EGFR gene mutations in subgroups of newly diagnosed non-small cell lung cancer patients based on clinical and pathological features
暂未订购
导出
摘要 目的分析初治非小细胞肺癌(non-small cell lung cancer,NSCLC)患者肺原发灶EGFR(epidermal growth factor receptor,EGFR)基因突变状态与临床病理特征的相关性,为临床EGFR-TKIs(tyrosine kinase inhibitors,TKIs)用药提供依据。方法收集第三军医大学附属大坪医院应用增殖阻遏突变系统(amplification refractory mutation system,ARMs)进行EGFR突变分析253例初治非小细胞肺癌患者的性别、年龄、吸烟史、KPS(Karnofsky performance status,KPS)评分、组织病理类型、TNM临床分期以及伴有脑转移患者的脑转移灶数量、确诊肺癌至诊断脑转移时间(brain metastasis time from diagnosis of lung cancer,BMT)和颅外转移状况等临床病理资料,应用χ2检验分析EGFR突变状态与各临床病理特征的关系。结果 253例初治NSCLC患者,EGFR基因敏感型突变率42.3%(107/253),其中EGFR基因第19、21外显子突变比例分别为70.1%(75/107)、39.1%(32/107),而EGFR基因20外显子TKIs耐药型突变率0.8%(2/253)。女性、无吸烟史、腺癌的肺原发灶EGFR基因敏感型突变率明显高于男性、有吸烟史、非腺癌患者,分别为70.2%(66/94)vs 25.8%(41/61)、60.9%(81/133)vs 18.1%(19/105)和50.0%(103/206)vs 8.5%(4/47),两者有显著性差异(P<0.05)。结论初治NSCLC患者肺原发灶存在较高(42.3%)EGFR基因敏感型突变,其中女性、腺癌、无吸烟史NSCLC患者EGFR基因敏感突变显著多见。 Ojeive o inveige he elionhip eween he EGFgene muion und linil phologil fe- ueof NLpienwih iniil emen, nd o povide efeene folinil mediion of EGF-KI. Mehodo ollehe dum of EGFmuionuing n mplifiion efoy muion yem (M), linil nd phologil h- eiiof 253 pienwih newly dignoed NLin he Dping Hopil, hid Miliy Medil Univeiy fom July 2011 o My 2013. he linil nd phologil heiiinluded ex, ge, moking u, KP(Knofky pefomne u), hiophologie ype, NM linil ge.In ddiion, 31 of 253 pienhve in mee, o hee pien, liniophologiel feueinlude he numeof in mee, M(in meiime fom dignoiof lung ne), pimy umoonolled ono, exnil meeu. he elionhip eween muion uof pulmony leion nd linil phologil feuewee nlyzed. eulIn hee 253 pienwih newly dignoed, he muion eof EG- Fgene foKIeniiviy wee 42. 3% (107/253), nd he muion eof exon 19 nd 21 wee 70. 1% (75/107), 39. 1% (32/ 107) epeively. he muion eof exon 20 wih EGFgene foKIeine wee 0. 8% (2/253). omped wih mle, moke, non-denoinom, he muion eof pimy lung ne'EGFgene foKIeniiviy wee highein femle, non-moke, d , nd he muionewee 70. 2% (66/ 94) v25.8% (41/61), 60. 9% (81/ 133) v18. 1% (19/105) nd 50. 0% (103/206) v8. 5% (4/47) epeively. Ihignifindiffeene eween hem(P〈 0. 05). onluion 42. 3% of newly dignoed NLpienhve muion of EGFgene foKIeniiviy, mong heehe muionof exon 19 nd 21 e minly oniued, nd he muionlgely find in femle, denoeeinom, non- moke.
出处 《西部医学》 2014年第1期11-15,共5页 Medical Journal of West China
基金 国家自然科学基金(81101783 81272499) 吴阶平医学基金会基金(320.6799.1132)
关键词 非小细胞肺癌 EGFR基因 表皮生长因子受体 酪氨酸激酶抑制剂 NSCLC EGFR gen Epidermal growth factor reeeptor Tyrosine kinase inhibitors
  • 相关文献

参考文献15

  • 1Jemal A,Siegel R,Ward E. Cancer statistics[J].{H}CA-A Cancer Journal for Clinicians,2008,(02):71-96.
  • 2Kin ES,Hirsh V,Mok T. Gefitinib versus docetaxel in previously treated non-small-cell lun cancer (INTEREST):a randomised phase Ⅲ trial[J].{H}LANCET,2008,(9652):1809-1818.
  • 3Paez JG,Janne PA,Lee JC. EGFR mutations in lung cancer:Correlation with clinical response to gefitinib therapy[J].{H}SCIENCE,2004.1497-1500.
  • 4Sholl LM,Xiao Y,Joshi V. EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH,CISH,and immunohistochemistry[J].{H}American Journal of Clinical Pathology,2010.922-934.
  • 5Mok TS,Wu YL,Thongprasert S. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma[J].{H}New England Journal of Medicine,2009.947-957.
  • 6Zhou C,Wu YL,Chen G. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,CTONG-0802):a multicentre,open-label,randomised,phase 3 study[J].{H}LANCET ONCOLOGY,2011,(08):735-742.
  • 7Ellison G,Donald E,McWalter G. A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples[J].{H}Journal of Experimental and Clinical Cancer Research,2010.132.
  • 8Eberhard D A,Johnson B E,Amler L C. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib[J].{H}Journal of Clinical 0ncology,2005,(25):5900-5909.
  • 9Yamamoto H,Toyooka S,Mitsudomi T. Impact of EGFR mutation analysis in non-small cell lung cancer[J].{H}Lung Cancer,2009,(03):315-321.
  • 10Chang A,Parikh P,Thongprasert S. Gefitinib (IRESSA)in patients of Asian origin with refractory advanced non-small cell lung cancer:subset analysis from the ISEL study[J].J Thome Oncol,2006,(08):847-855.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部